Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acura Pharmaceuticals, a specialty pharmaceutical company engaged in manufacture, research and development of product candidates, has reported revenues of $292,000 for the third quarter ended 30 September 2010, compared to $808,000 for the same period in 2009.
Subscribe to our email newsletter
Acura has posted a net loss of $2.55m for the third quarter 2010, or $0.05 loss per diluted share, compared to net loss of $3.95m, or $0.09 loss per diluted share, for the comparable period in 2009.
Loss from operations was $2.57m, compared to $3.97m for the comparable period in 2009.
For the nine months ended 30 September 2010, Acura has posted a revenue of $2.95m, compared to $3.09m for the year ago period.
Acura has posted a net loss of $9.78m, or $0.21 loss per diluted share for the nine months ended 30 September 2010, compared to net loss of $11.75m, or $0.26 loss per diluted share, for the year ago period.
Loss from operations was $9.79m, compared to $9.42m for the year ago period.